分類彙整：公司新聞

美國UBI集團暨聯生藥(6471)與聯亞藥(6562)董事長王長怡博士受邀於25日在揚州月畔灣酒店由揚州國家高新技術產業開發區舉辦的「2018揚州生物醫藥論壇」中給予專題演講。 繼續閱讀 →

Candidates Generated with United Neuroscience Endobody Technology Will be Tested at the Center for Alzheimer’s and Neurodegenerative Diseases 繼續閱讀 →

DUBLIN, March 22, 2018 /PRNewswire/ — United Neuroscience, Ltd., (UNS), today announced that it has entered a research collaboration agreement with the Ronald Melki laboratory at the French National Center for Scientific Research (CNRS) to investigate applications of the United Neuroscience Endobody technology platform in targeting pathogenic forms of alpha-synuclein protein. Under the agreement, United Neuroscience will contribute novel candidates targeting specific protein aggregates using the Endobody technology platform. Researchers in the CNRS laboratory will provide expertise in characterization of these candidates for key properties for their potential in generating therapeutics for Parkinson’s disease and other synucleinopathies. 繼續閱讀 →

LOS ANGELES, March 15, 2018 /PRNewswire-USNewswire/ — The Society for Brain Mapping and Therapeutics (SBMT) officially announced today they will hold their 15th Annual World Congress at the Millennium Biltmore Hotel in DTLA from April 13-15, 2018. The event will include more than 400 scientists, engineers, physicians and surgeons where they will discuss pioneering technologies, policies and science advances in the fields including: multimodality imaging, nanoneurosurgery, nanobioelectronics, neurophotonics, cellular therapeutics (stem cell and neuro-immunotherapey), supercomputing, robotics (brain computer interface), neural transplantation and repair (double hand transplants), neuroengineering, Artificial Intelligence (AI), augmented reality and virtual reality in clinical neuroscience as well as computational and predictive modeling. 繼續閱讀 →

United BioPharma (UBP, 6471) announced today that the company receives the approval from Thailand FDA an IND (Investigational New Drug) application for a multi-nation, multi-center, Phase III clinical trial with UB-421 monotherapy as HAART (Highly Active Anti-retroviral Therapy ) substitution in HIV infected patients. 繼續閱讀 →

聯生藥今日(6471)表示，其治療愛滋病單株抗體新藥UB-421規劃在台灣、中國與泰國三個地區執行之多國多中心HAART (Highly Active Anti-retroviral Therapy，抗反轉錄病毒療法) 取代性療法第三期臨床試驗，繼2017年11月7日獲得台灣衛福部食藥署 (TFDA) 核准後，今已於2018年3月14日獲得泰國食品藥品監督管理局(ThaiFDA)核發臨床藥物進口許可證(import license) ，核准三期UB-421臨床試驗之進行。 繼續閱讀 →

聯生藥(6471) 今日表示，與美國奇異醫療集團生命科學部(GE Healthcare Life Sciences)再度攜手合作，將在揚州高新技術産業開發區打造世界先進的單株抗體藥物生產基地。 繼續閱讀 →

United BioPharma (UBP, 6471) announced that construction will begin on a state-of-the-art biopharmaceutical manufacturing plant in China to support the development of key innovator, biobetter and biosimilar monoclonal antibody(mAb) drugs for the China market through its subsidiary, UBP (Yangzhou). 繼續閱讀 →

聯生藥(6471) 今日表示，將正式啟動中國抗體藥物建廠計畫。

聯生藥為拓展中國龐大且剛起步的單株抗體藥物市場，經兩年多的考察，於2017年4月與揚州高新技術産業開發區（以下簡稱「揚州高新區」）簽署合作協議，於揚州高新區建立蛋白質藥物生產基地，並接續於上海與揚州分別成立聯藥(上海)生物科技與聯生藥(揚州)生物醫藥兩家子公司，作為進軍中國醫藥市場之研發中心與抗體藥物生產基地。 繼續閱讀 →

DUBLIN, Feb. 28, 2018 /PRNewswire/ — United Neuroscience, Ltd., (UNS), today announced that the company will present at the upcoming 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT) conference being held March 7-10, 2018. Presentation details are as follows: 繼續閱讀 →

DUBLIN, Jan. 29, 2018 /PRNewswire/ — United Neuroscience, Inc. (UNS) today announced plans for the development of a vaccine for the prevention of chronic traumatic encephalopathy (CTE). CTE is a progressive neurodegenerative disorder that affects people with a history of repetitive brain trauma, including athletes who participate in contact sports – football, hockey, boxing and others – as well as military personnel and victims of domestic violence. 繼續閱讀 →

United Neuroscience’s Mei Mei Hu Interviewed by MSNBC’s Ali Velshi 繼續閱讀 →

臺灣醫療科技展已於12月10日圓滿落成，聯亞集團一連4天的展出，吸引許多民眾蒞臨參與，創新研發技術、重磅新藥產品以及展場設計與概念深獲專業人士及參觀民眾好評，展現聯亞集團堅強的研發實力以及豐碩成果。 繼續閱讀 →

誠摯邀請您參加12月7日至10日國內首次盛大舉辦之台灣醫療科技展，聯亞集團(聯亞生技、聯生藥、聯亞藥、聯腦科學)將帶您窺探強大的免疫學能量為全人類健康帶來的福祉及奇蹟！展期間亦有多場聯亞集團旗下各公司之專業講座，將為您介紹聯亞集團的沿革、成果優勢與未來展望。歡迎蒞臨攤位M505a參觀指教！ 繼續閱讀 →

聯合生物製藥股份有限公司（聯生藥）為加速各項產品臨床進展，於竹北生醫園區建置「P2+生物分析實驗室」，並導入CWA15793生物風險管理系統，經財團法人全國認證基金會現場查訪，以零缺失的高度評價通過本次審查，並獲衛生福利部疾病管制署獲頒「楷模獎」的殊榮。 繼續閱讀 →